Enlivex Therapeutics to Discuss Phase I Trial Data
Ticker: ENLV · Form: 6-K · Filed: Mar 4, 2025 · CIK: 1596812
Sentiment: neutral
Topics: clinical-trial-update, investor-event, biotech
TL;DR
Enlivex Therapeutics hosting webinar March 5th to discuss positive Phase I interim data.
AI Summary
On March 4, 2025, Enlivex Therapeutics Ltd. announced a webinar for investors scheduled for March 5, 2025, at 11:00 a.m. ET. The webinar will discuss positive interim six-month data from its Phase I clinical trial.
Why It Matters
This announcement provides investors with an opportunity to hear directly about promising clinical trial results, which could impact the company's future development and stock performance.
Risk Assessment
Risk Level: medium — Clinical trial data can be highly speculative and subject to regulatory approval, creating inherent risk for investors.
Key Players & Entities
- Enlivex Therapeutics Ltd. (company) — Registrant
- March 5, 2025 (date) — Webinar date
- 11:00 a.m. ET (time) — Webinar time
- Phase I (clinical_trial_phase) — Clinical trial stage
FAQ
What specific positive interim data will be discussed from the Phase I trial?
The filing states that positive interim six-month data from the Phase I trial will be discussed, but does not provide specific details within this report.
What is the purpose of the investor webinar?
The purpose of the webinar is to discuss the positive interim six-month data from the Phase I clinical trial.
When is the investor webinar scheduled to take place?
The investor webinar is scheduled for March 5, 2025, at 11:00 a.m. ET.
What is Enlivex Therapeutics Ltd.'s primary business?
Enlivex Therapeutics Ltd. is in the business of pharmaceutical preparations, as indicated by its SIC code [2834].
Has Enlivex Therapeutics Ltd. changed its name previously?
Yes, Enlivex Therapeutics Ltd. was formerly known as Bioblast Pharma Ltd. (name change effective September 19, 2016) and prior to that, BIO BLAST PHARMA LTD. (name change effective January 13, 2014).
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on March 4, 2025 regarding Enlivex Therapeutics Ltd. (ENLV).